Swetha Kambhampati, MD, on the Potential of Bringing Brexu-cel to Earlier Treatment Settings

Video

The assistant professor in the Division of Lymphoma at City of Hope discussed the potential implications of real-world data she presented at ASCO’s 2023 conference.

“I think at least in this largest real-world study to date, the findings support considering use of brexu-cel in earlier lines because we saw higher response rates in patients who are less heavily pretreated even when adjusting for other baseline characteristics... In the multivariate analysis, we found a higher likelihood of achieving complete response in patients who had 1 to 2 prior lines [of therapy, compared to patients who had 3 or more lines]. This suggests that using this therapy earlier may improve outcomes. Of course, this needs further evaluation, but I think, mechanistically, it's reasonable and makes sense. Patients, when they're less heavily pretreated, have improved T-cell quality, and this may impact the outcomes of brexu-cel.”

Kite Pharma’s brexucabtagene autoleucel (brexu-cel, Tecartus) is a chimeric antigen receptor T-cell (CAR-T) therapy currently FDA-approved for use in the second-line setting for adult patients with mantle cell lymphoma (MCL).1 Its approval in MCL was based on results from the phase 2 ZUMA-2 clinical trial (NCT02601313). Notably, all patients in ZUMA-2 had received prior treatment with BTK inhibitor; however, the FDA indication for brexu-cel does not require a specific prior treatment regimen.2 As such, in real-world settings, the treatment histories of patients with MCL receiving brexu-cel are more varied.

Swetha Kambhampati, MD, an assistant professor in the Division of Lymphoma at City of Hope, gave a talk entitled “Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (r/r) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment” at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois. The talk covered an analysis of real-world outcomes from a subgroup of 380 patients who received brexu-cel and were registered in the Center for International Blood and Marrow Transplant Research (CIBMTR) observational database.

In an interview with CGTLive™’s sister publication OncLive™, Kambhampati gave an overview of the data she presented at the conference, noting that in multivariate analysis, patients who had received only 1 to 2 prior lines of therapy had 2-fold higher chances of achieving a complete response versus patients who had received 3 or more prior lines of therapy. She also discussed the implications of the results, suggesting that they could provide support for investigating the possibility of bringing brexu-cel into earlier treatment settings. Although, she emphasized that more research and longer follow-up times are needed.

Click here for more coverage of ASCO 2023.

REFERENCES
1. U.S. FDA Approves Kite’s Tecartus™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company. July 24, 2020. Accessed June 20, 2023. https://www.businesswire.com/news/home/20200724005428/en/
2. Kambhampati S, Ahmed N, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (r/r) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment. Presented at: the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois. Abstract #7507
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
© 2024 MJH Life Sciences

All rights reserved.